FDA Adverse Event Injury Summary report: N

XIENCE ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 6528647 · Received April 27, 2017

Report

Report Number
2024168-2017-03726
Event Type
Injury
Date Received
April 27, 2017
Date of Event
April 4, 2017
Report Date
April 27, 2017
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
UDI-DI
08717648199271
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). CONCOMITANT MEDICAL PRODUCTS: GUIDE WIRE: RINATO, GUIDE CATHETER: HYPERION. THE DEVICE WAS NOT RETURNED FOR EVALUATION. A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, CANNOT BE DETERMINED. A REVIEW OF THE LOT HISTORY RECORD IDENTIFIED NO MANUFACTURING NONCONFORMITIES ISSUED TO THE REPORTED LOT THAT WOULD HAVE CONTRIBUTED TO THIS EVENT. THERE IS NO INDICATION OF A PRODUCT QUALITY ISSUE WITH RESPECT TO THE DESIGN, MANUFACTURE, OR LABELING OF THE DEVICE. THE TENKU RX IS FILED UNDER A SEPARATE MEDWATCH REPORT NUMBER.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PROCEDURE WAS TO TREAT A MODERATELY TORTUOUS, MILDLY CALCIFIED, CONCENTRIC, AND DE NOVO FIRST DIAGONAL ARTERY THAT WAS 90% STENOSED. AN UNSPECIFIED XIENCE ALPINE STENT WAS IMPLANTED IN THE PROXIMAL LEFT ANTERIOR DESCENDING ARTERY WHEN PLAQUE SHIFT OCCURRED AT THE ENTRANCE OF THE FIRST DIAGONAL. A 1.5 X 12 MM RX TENKU WAS BEING USED TO DILATE THE VESSEL WHEN THE BALLOON RUPTURED ON THE FIRST INFLATION AFTER 10 SECONDS AT 6 ATMOSPHERES. A NON-ABBOTT BALLOON WAS SUCCESSFULLY USED TO COMPLETE THE PROCEDURE. THERE WAS NO CLINICALLY SIGNIFICANT DELAY IN PROCEDURE AND NO ADVERSE PATIENT EFFECTS. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
307354 XIENCE ALPINE EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 6110741 08717648199271

Patients

Seq Age Sex Outcome Treatment
1 78 YR Other